➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
Dow
Express Scripts
McKinsey

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESKETAMINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Esketamine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00847418 Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine Completed University Hospital, Basel, Switzerland Phase 1 2009-02-01 The purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.
NCT01640080 A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression Completed Janssen Research & Development, LLC Phase 2 2012-06-01 The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
NCT01780259 A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants Completed Janssen Research & Development, LLC Phase 1 2012-12-01 The primary purpose of the study is to evaluate the pharmacokinetics (what the body does to the medication) of intranasally (through the nose) administered esketamine in healthy participants.
NCT01980303 A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers Completed Janssen Research & Development, LLC Phase 1 2013-11-01 The purpose of this Phase 1 study is to characterize the pharmacokinetic profile (what the body does to the medication) of esketamine when given by the intranasal route (through the nose) to healthy adult Japanese and Caucasian participants.
NCT01998958 A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression Completed Janssen Research & Development, LLC Phase 2 2014-01-01 The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants with treatment-resistant depression (TRD).
NCT02060929 A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device Completed Janssen Research & Development, LLC Phase 1 2013-10-01 The primary purpose of the study is to evaluate the pharmacokinetics (what the body does to the medication) of intranasally (through the nose) administered esketamine using a device with and without a nasal guide in healthy participants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Esketamine Hydrochloride

Condition Name

Condition Name for Esketamine Hydrochloride
Intervention Trials
Healthy 14
Depressive Disorder, Treatment-Resistant 6
Depression 5
Major Depressive Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Esketamine Hydrochloride
Intervention Trials
Depression 26
Depressive Disorder 25
Depressive Disorder, Treatment-Resistant 15
Depressive Disorder, Major 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Esketamine Hydrochloride

Trials by Country

Trials by Country for Esketamine Hydrochloride
Location Trials
United States 215
Belgium 18
Poland 13
Canada 12
China 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Esketamine Hydrochloride
Location Trials
California 13
New York 13
Maryland 12
Texas 11
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Esketamine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Esketamine Hydrochloride
Clinical Trial Phase Trials
Phase 4 8
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Esketamine Hydrochloride
Clinical Trial Phase Trials
Recruiting 22
Not yet recruiting 21
Completed 18
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Esketamine Hydrochloride

Sponsor Name

Sponsor Name for Esketamine Hydrochloride
Sponsor Trials
Janssen Research & Development, LLC 33
Celon Pharma SA 3
Second Affiliated Hospital, School of Medicine, Zhejiang University 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Esketamine Hydrochloride
Sponsor Trials
Industry 40
Other 34
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Baxter
Harvard Business School
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.